Abbott Laboratories (ABT) 10-Year Financial Performance & Capital Metrics

ABT • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesStructural Heart & Valve Devices

AboutAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.Show more

Revenue $41.95B +4.6%
EBITDA $10.04B +3.8%
Net Income $13.4B +134.2%
EPS (Diluted) 7.64 +133.6%
Gross Margin 50.83% +1.8%
EBITDA Margin 23.94% -0.8%
Operating Margin 16.27% +1.4%
Net Margin 31.95% +123.9%
ROE 30.91% +104.5%
ROIC 9.9% -4.8%
Debt/Equity 0.32 -22.0%
Interest Coverage 11.32 +22.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 21.7%
✓Strong 5Y profit CAGR of 29.4%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 15.1% free cash flow margin
✓11 consecutive years of dividend growth
✓Healthy 5Y average net margin of 18.3%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.56%

5Y5.63%

3Y-0.88%

TTM6.37%

Profit (Net Income) CAGR

10Y19.36%

5Y29.45%

3Y23.76%

TTM142.36%

EPS CAGR

10Y17.68%

5Y29.97%

3Y24.7%

TTM142.5%

ROCE

10Y Avg9.34%

5Y Avg11.89%

3Y Avg11.82%

Latest10.78%

Peer Comparison

Structural Heart & Valve Devices

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
LIVNLivaNova PLC	3.35B	61.33	52.87	8.66%	-16.12%	-18.79%	4.06%	0.51
ABTAbbott Laboratories	216.14B	124.30	16.27	4.59%	31.88%	27.26%	2.94%	0.32
EWEdwards Lifesciences Corporation	48.65B	83.84	12.03	8.57%	23.19%	13.37%	0.6%	0.07
AVRAnteris Technologies Global Corp.	184.98M	4.49	-1.19	-1.16%	-39.42%	-25.1%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	20.41B	20.85B	27.39B	30.58B	31.9B	34.61B	43.08B	43.65B	40.11B	41.95B
Revenue Growth %	0.01%	0.02%	0.31%	0.12%	0.04%	0.08%	0.24%	0.01%	-0.08%	0.05%
Cost of Goods Sold+	9.45B	9.61B	14.32B	14.76B	15.21B	17.23B	19.86B	21.33B	20.07B	20.63B
COGS % of Revenue	0.46%	0.46%	0.52%	0.48%	0.48%	0.5%	0.46%	0.49%	0.5%	0.49%
Gross Profit+	10.96B	11.24B	13.07B	15.82B	16.69B	17.38B	23.21B	22.32B	20.04B	21.32B
Gross Margin %	0.54%	0.54%	0.48%	0.52%	0.52%	0.5%	0.54%	0.51%	0.5%	0.51%
Gross Profit Growth %	0.04%	0.03%	0.16%	0.21%	0.05%	0.04%	0.34%	-0.04%	-0.1%	0.06%
Operating Expenses+	8.01B	8B	11.09B	11.98B	12.1B	12.09B	14.01B	13.96B	13.6B	14.47B
OpEx % of Revenue	0.39%	0.38%	0.41%	0.39%	0.38%	0.35%	0.33%	0.32%	0.34%	0.35%
Selling, General & Admin	6.64B	6.64B	8.96B	9.69B	9.69B	9.67B	11.28B	11.11B	10.88B	11.65B
SG&A % of Revenue	0.33%	0.32%	0.33%	0.32%	0.3%	0.28%	0.26%	0.25%	0.27%	0.28%
Research & Development	1.37B	1.36B	2.13B	2.29B	2.41B	2.42B	2.74B	2.85B	2.72B	2.82B
R&D % of Revenue	0.07%	0.07%	0.08%	0.07%	0.08%	0.07%	0.06%	0.07%	0.07%	0.07%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	2.95B	3.25B	1.97B	3.84B	4.59B	5.29B	9.2B	8.36B	6.43B	6.83B
Operating Margin %	0.14%	0.16%	0.07%	0.13%	0.14%	0.15%	0.21%	0.19%	0.16%	0.16%
Operating Income Growth %	0.01%	0.1%	-0.39%	0.95%	0.19%	0.15%	0.74%	-0.09%	-0.23%	0.06%
EBITDA+	4.42B	4.6B	4.99B	7.12B	7.61B	8.62B	12.74B	11.63B	9.68B	10.04B
EBITDA Margin %	0.22%	0.22%	0.18%	0.23%	0.24%	0.25%	0.3%	0.27%	0.24%	0.24%
EBITDA Growth %	0.01%	0.04%	0.08%	0.43%	0.07%	0.13%	0.48%	-0.09%	-0.17%	0.04%
D&A (Non-Cash Add-back)	1.47B	1.35B	3.02B	3.28B	3.01B	3.33B	3.54B	3.27B	3.24B	3.22B
EBIT	3.36B	1.72B	3.11B	3.6B	4.89B	5.68B	8.62B	8.62B	7.36B	7.62B
Net Interest Income+	-73M	-205M	-756M	-624M	-724M	-662M	-367M	-132M	-313M	-259M
Interest Income	105M	99M	124M	105M	94M	46M	43M	183M	385M	344M
Interest Expense	178M	304M	880M	729M	818M	708M	410M	315M	698M	603M
Other Income/Expense	234M	-1.84B	259M	-971M	-514M	-323M	-989M	-56M	229M	188M
Pretax Income+	3.18B	1.41B	2.23B	2.87B	4.08B	4.97B	8.21B	8.31B	6.66B	7.01B
Pretax Margin %	0.16%	0.07%	0.08%	0.09%	0.13%	0.14%	0.19%	0.19%	0.17%	0.17%
Income Tax+	577M	350M	1.88B	539M	390M	497M	1.14B	1.37B	941M	-6.39B
Effective Tax Rate %	1.39%	0.99%	0.21%	0.82%	0.9%	0.9%	0.86%	0.83%	0.86%	1.91%
Net Income+	4.42B	1.4B	477M	2.37B	3.69B	4.5B	7.07B	6.93B	5.72B	13.4B
Net Margin %	0.22%	0.07%	0.02%	0.08%	0.12%	0.13%	0.16%	0.16%	0.14%	0.32%
Net Income Growth %	0.94%	-0.68%	-0.66%	3.96%	0.56%	0.22%	0.57%	-0.02%	-0.17%	1.34%
Net Income (Continuing)	2.61B	1.06B	353M	2.33B	3.69B	4.47B	7.07B	6.93B	5.72B	13.4B
Discontinued Operations	1.82B	337M	124M	34M	0	24M	0	0	0	0
Minority Interest	115M	179M	201M	198M	213M	219M	222M	219M	224M	237M
EPS (Diluted)+	2.94	0.94	0.27	1.34	2.06	2.50	3.94	3.91	3.27	7.64
EPS Growth %	0.96%	-0.68%	-0.71%	3.96%	0.54%	0.21%	0.58%	-0.01%	-0.16%	1.34%
EPS (Basic)	3.00	0.95	0.27	1.35	2.07	2.52	3.97	3.94	3.30	7.67
Diluted Shares Outstanding	1.51B	1.48B	1.75B	1.77B	1.78B	1.79B	1.79B	1.76B	1.75B	1.75B
Basic Shares Outstanding	1.47B	1.47B	1.74B	1.76B	1.77B	1.77B	1.77B	1.75B	1.73B	1.73B
Dividend Payout Ratio	0.33%	1.1%	3.88%	0.83%	0.62%	0.57%	0.45%	0.48%	0.62%	0.29%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.15B	26.78B	20.15B	14.63B	15.67B	20.44B	24.24B	25.22B	22.67B	23.66B
Cash & Short-Term Investments	6.13B	18.77B	9.61B	4.09B	4.14B	7.15B	10.25B	10.17B	7.28B	7.97B
Cash Only	5B	18.62B	9.41B	3.84B	3.86B	6.84B	9.8B	9.88B	6.9B	7.62B
Short-Term Investments	1.12B	155M	203M	242M	280M	310M	450M	288M	383M	351M
Accounts Receivable	3.42B	3.25B	5.25B	5.18B	5.42B	6.41B	6.49B	6.22B	6.57B	6.92B
Days Sales Outstanding	61.14	56.85	69.95	61.86	62.07	67.65	54.97	51.99	59.74	60.25
Inventory	2.6B	2.43B	3.6B	3.8B	4.32B	5.01B	5.16B	6.17B	6.57B	6.19B
Days Inventory Outstanding	100.44	92.46	91.76	93.9	103.57	106.17	94.77	105.63	119.47	109.61
Other Current Assets	2.01B	2.32B	1.69B	1.57B	1.79B	1.87B	2.35B	2.66B	2.26B	2.57B
Total Non-Current Assets+	29.85B	28.23B	56.1B	52.54B	52.22B	52.11B	50.96B	49.21B	50.54B	57.76B
Property, Plant & Equipment	5.73B	5.71B	7.61B	7.56B	8.97B	10.13B	10.11B	10.28B	11.28B	11.73B
Fixed Asset Turnover	3.56x	3.66x	3.60x	4.04x	3.56x	3.42x	4.26x	4.25x	3.56x	3.58x
Goodwill	9.64B	7.68B	24.02B	23.25B	23.2B	23.74B	23.23B	22.8B	23.68B	23.11B
Intangible Assets	5.56B	4.54B	21.47B	18.94B	17.02B	14.78B	12.74B	10.45B	8.81B	6.65B
Long-Term Investments	4.04B	2.95B	883M	897M	931M	1.03B	903M	766M	799M	886M
Other Non-Current Assets	492M	3.35B	2.12B	1.89B	2.1B	2.42B	3.97B	4.92B	5.97B	15.38B
Total Assets+	44B	55.01B	76.25B	67.17B	67.89B	72.55B	75.2B	74.44B	73.21B	81.41B
Asset Turnover	0.46x	0.38x	0.36x	0.46x	0.47x	0.48x	0.57x	0.59x	0.55x	0.52x
Asset Growth %	0%	0.25%	0.39%	-0.12%	0.01%	0.07%	0.04%	-0.01%	-0.02%	0.11%
Total Current Liabilities+	9.19B	6.66B	8.91B	9.01B	10.86B	11.91B	13.11B	15.49B	13.84B	14.16B
Accounts Payable	1.08B	1.18B	2.4B	2.98B	3.25B	3.95B	4.41B	4.61B	4.29B	4.2B
Days Payables Outstanding	41.77	44.75	61.21	73.59	78.03	83.59	81.01	78.84	78.1	74.24
Short-Term Debt	3.13B	1.32B	714M	207M	1.68B	461M	999M	2.48B	1.32B	1.75B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	3.8B	3.22B	4.3B	4.34B	4.46B	5.72B	5.77B	6.5B	6.13B	5.91B
Current Ratio	1.54x	4.02x	2.26x	1.62x	1.44x	1.72x	1.85x	1.63x	1.64x	1.67x
Quick Ratio	1.26x	3.65x	1.86x	1.20x	1.04x	1.30x	1.46x	1.23x	1.16x	1.23x
Cash Conversion Cycle	119.8	104.56	100.5	82.17	87.6	90.23	68.73	78.79	101.11	95.63
Total Non-Current Liabilities+	13.49B	27.63B	36.24B	27.44B	25.72B	27.64B	26.07B	22.04B	20.55B	19.36B
Long-Term Debt	5.87B	20.68B	27.21B	19.36B	16.66B	18.53B	17.3B	14.52B	13.6B	12.63B
Capital Lease Obligations	0	0	0	0	755M	902M	956M	943M	949M	896M
Deferred Tax Liabilities	3.56B	2.7B	2.01B	2.06B	2.13B	2.15B	2.07B	1.84B	1.22B	1.37B
Other Non-Current Liabilities	4.06B	4.25B	7.02B	6.02B	6.18B	6.06B	5.74B	4.74B	4.78B	4.46B
Total Liabilities	19.92B	31.95B	45.15B	36.45B	36.59B	39.55B	39.17B	37.53B	34.39B	33.51B
Total Debt+	9B	22.01B	27.92B	19.57B	19.1B	19.89B	19.25B	17.95B	15.87B	15.28B
Net Debt	4B	3.39B	18.52B	15.72B	15.24B	13.05B	9.45B	8.06B	8.98B	7.66B
Debt / Equity	0.42x	1.06x	0.90x	0.64x	0.61x	0.60x	0.53x	0.49x	0.41x	0.32x
Debt / EBITDA	2.04x	4.78x	5.59x	2.75x	2.51x	2.31x	1.51x	1.54x	1.64x	1.52x
Net Debt / EBITDA	0.90x	0.74x	3.71x	2.21x	2.00x	1.51x	0.74x	0.69x	0.93x	0.76x
Interest Coverage	16.57x	10.69x	2.24x	5.27x	5.61x	7.47x	22.44x	26.55x	9.22x	11.32x
Total Equity+	21.33B	20.72B	31.1B	30.72B	31.3B	33B	36.02B	36.91B	38.83B	47.9B
Equity Growth %	-0.01%	-0.03%	0.5%	-0.01%	0.02%	0.05%	0.09%	0.02%	0.05%	0.23%
Book Value per Share	14.16	13.97	17.78	17.36	17.57	18.48	20.14	20.92	22.20	27.40
Total Shareholders' Equity	21.21B	20.54B	30.9B	30.52B	31.09B	32.78B	35.8B	36.69B	38.6B	47.66B
Common Stock	12.73B	13.03B	23.21B	23.51B	23.85B	24.14B	24.47B	24.71B	24.87B	25.15B
Retained Earnings	25.76B	25.57B	23.98B	24.56B	25.85B	27.63B	31.53B	35.26B	37.55B	47.26B
Treasury Stock	-10.62B	-10.79B	-10.22B	-9.96B	-10.15B	-10.04B	-11.82B	-15.23B	-15.98B	-16.84B
Accumulated OCI	-6.66B	-7.26B	-6.06B	-7.59B	-8.46B	-8.95B	-8.37B	-8.05B	-7.84B	-7.91B
Minority Interest	115M	179M	201M	198M	213M	219M	222M	219M	224M	237M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.97B	3.2B	5.57B	6.3B	6.14B	7.9B	10.53B	9.58B	7.26B	8.56B
Operating CF Margin %	0.15%	0.15%	0.2%	0.21%	0.19%	0.23%	0.24%	0.22%	0.18%	0.2%
Operating CF Growth %	-0.19%	0.08%	0.74%	0.13%	-0.03%	0.29%	0.33%	-0.09%	-0.24%	0.18%
Net Income	1.58B	1.38B	477M	2.37B	3.69B	4.5B	7.07B	6.93B	5.72B	13.4B
Depreciation & Amortization	1.47B	1.35B	3.02B	3.28B	3.01B	3.33B	3.54B	3.27B	3.24B	3.22B
Stock-Based Compensation	292M	310M	406M	477M	519M	546M	640M	685M	644M	673M
Deferred Taxes	314M	248M	-1.16B	293M	0	0	0	0	0	0
Other Non-Cash Items	-539M	1.43B	912M	32M	247M	425M	55M	215M	126M	482M
Working Capital Changes	-156M	-1.51B	1.92B	-148M	-1.33B	-892M	-771M	-1.52B	-2.48B	-9.22B
Change in Receivables	-171M	-177M	-207M	-190M	-275M	-924M	-383M	-68M	-356M	-691M
Change in Inventory	-257M	-98M	249M	-514M	-593M	-493M	-456M	-1.41B	-232M	-58M
Change in Payables	-742M	-652M	615M	747M	220M	1.77B	1.29B	420M	-760M	356M
Cash from Investing+	406M	-248M	-9.62B	-1.36B	-1.81B	-2.21B	-2.01B	-1.74B	-3.13B	-2.34B
Capital Expenditures	-1.11B	-1.12B	-1.14B	-1.39B	-1.64B	-2.18B	-1.89B	-1.78B	-2.2B	-2.21B
CapEx % of Revenue	0.05%	0.05%	0.04%	0.05%	0.05%	0.06%	0.04%	0.04%	0.05%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	52M	42M	35M	48M	27M	19M	26M	22M	22M	9M
Cash from Financing+	-2.24B	11.15B	-5.28B	-10.39B	-4.29B	-2.78B	-5.49B	-7.64B	-7.09B	-5.4B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.44B	-1.54B	-1.85B	-1.97B	-2.27B	-2.56B	-3.2B	-3.31B	-3.56B	-3.84B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	297M	53M	-1.05B	271M	298M	234M	255M	167M	167M	264M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.86B	2.08B	4.43B	4.91B	4.5B	5.72B	8.65B	7.8B	5.06B	6.35B
FCF Margin %	0.09%	0.1%	0.16%	0.16%	0.14%	0.17%	0.2%	0.18%	0.13%	0.15%
FCF Growth %	-0.29%	0.12%	1.13%	0.11%	-0.08%	0.27%	0.51%	-0.1%	-0.35%	0.26%
FCF per Share	1.23	1.40	2.54	2.77	2.53	3.20	4.83	4.42	2.89	3.63
FCF Conversion (FCF/Net Income)	0.67x	2.29x	11.68x	2.66x	1.66x	1.76x	1.49x	1.38x	1.27x	0.64x
Interest Paid	166M	181M	917M	845M	677M	549M	544M	563M	662M	604M
Taxes Paid	631M	620M	570M	740M	930M	970M	1.94B	1.86B	1.48B	1.72B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	20.59%	6.66%	1.84%	7.66%	11.89%	13.98%	20.49%	19.01%	15.11%	30.91%
Return on Invested Capital (ROIC)	8.72%	9.86%	4.01%	6%	7.41%	8.57%	15.08%	13.87%	10.4%	9.9%
Gross Margin	53.71%	53.92%	47.7%	51.75%	52.32%	50.21%	53.89%	51.14%	49.96%	50.83%
Net Margin	21.68%	6.71%	1.74%	7.74%	11.56%	12.99%	16.42%	15.88%	14.27%	31.95%
Debt / Equity	0.42x	1.06x	0.90x	0.64x	0.61x	0.60x	0.53x	0.49x	0.41x	0.32x
Interest Coverage	16.57x	10.69x	2.24x	5.27x	5.61x	7.47x	22.44x	26.55x	9.22x	11.32x
FCF Conversion	0.67x	2.29x	11.68x	2.66x	1.66x	1.76x	1.49x	1.38x	1.27x	0.64x
Revenue Growth	0.78%	2.2%	31.35%	11.64%	4.34%	8.48%	24.47%	1.34%	-8.12%	4.59%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Medical Devices	-	-	8.91B	9.44B	12.24B	11.79B	14.37B	14.69B	16.89B	18.99B
Medical Devices Growth	-	-	-	5.90%	29.69%	-3.69%	21.89%	2.23%	14.98%	12.43%
Diagnostic Products	4.65B	4.81B	5.62B	7.5B	7.71B	10.8B	15.64B	16.58B	9.99B	9.34B
Diagnostic Products Growth	-	3.59%	16.68%	33.46%	2.91%	40.09%	44.78%	6.01%	-39.77%	-6.48%
Nutritional Products	6.97B	6.9B	6.92B	7.23B	7.41B	7.65B	8.29B	7.46B	8.15B	8.41B
Nutritional Products Growth	-	-1.09%	0.38%	4.39%	2.49%	3.21%	8.46%	-10.07%	9.32%	3.18%
Established Pharmaceutical Products	3.72B	3.86B	4.29B	4.42B	4.49B	4.3B	4.72B	4.91B	5.07B	5.19B
Established Pharmaceutical Products Growth	-	3.74%	11.09%	3.15%	1.45%	-4.08%	9.64%	4.11%	3.14%	2.53%
Unallocated Amount to	2.27B	2.39B	1.65B	2B	57M	66M	-	-	-	-
Unallocated Amount to Growth	-	5.02%	-30.80%	20.84%	-97.14%	15.79%	-	-	-	-
Vascular Products	2.79B	2.9B	-	-	-	-	-	-	-	-
Vascular Products Growth	-	3.72%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	6.27B	6.49B	9.67B	10.84B	11.4B	13.02B	16.64B	18.14B	15.45B	16.32B
UNITED STATES Growth	-	3.44%	49.14%	12.05%	5.16%	14.25%	27.80%	9.01%	-14.83%	5.64%
Non-US	4.88B	4.99B	5.74B	11.21B	11.53B	12.58B	15.52B	14.84B	14.08B	14.85B
Non-US Growth	-	2.23%	15.07%	95.35%	2.84%	9.07%	23.33%	-4.34%	-5.10%	5.41%
D [E]	1B	1.04B	1.37B	1.62B	1.75B	2.11B	2.57B	2.34B	2.35B	2.54B
D [E] Growth	-	3.98%	30.84%	18.52%	8.15%	20.39%	22.01%	-9.02%	0.21%	8.27%
C [N]	1.8B	1.73B	2.15B	2.31B	2.35B	1.97B	2.39B	2.13B	2.25B	2.11B
C [N] Growth	-	-3.79%	24.19%	7.69%	1.51%	-16.24%	21.73%	-10.83%	5.63%	-6.21%
I [N]	1.05B	1.11B	1.24B	1.33B	1.4B	1.32B	1.56B	1.65B	1.75B	1.82B
I [N] Growth	-	5.79%	11.04%	7.76%	4.80%	-5.30%	17.99%	5.64%	6.12%	3.83%
C [H]	784M	766M	841M	1B	1.07B	1.14B	1.31B	1.34B	1.64B	1.75B
C [H] Growth	-	-2.30%	9.79%	19.50%	6.27%	6.74%	15.18%	1.75%	22.60%	6.65%
J [P]	895M	924M	1.25B	1.33B	1.44B	1.39B	1.7B	1.93B	1.51B	1.44B
J [P] Growth	-	3.24%	35.82%	5.66%	8.22%	-3.41%	22.29%	13.98%	-21.69%	-4.76%
N [L]	855M	830M	929M	930M	975M	1.08B	-	-	1.07B	1.12B
N [L] Growth	-	-2.92%	11.93%	0.11%	4.84%	11.18%	-	-	-	4.66%
CANADA	-	-	-	-	-	-	1.39B	1.28B	-	-
CANADA Growth	-	-	-	-	-	-	-	-7.58%	-	-
R [U]	483M	554M	664M	-	-	-	-	-	-	-
R [U] Growth	-	14.70%	19.86%	-	-	-	-	-	-	-
F [R]	375M	-	628M	-	-	-	-	-	-	-
F [R] Growth	-	-	-	-	-	-	-	-	-	-
B [R]	381M	410M	541M	-	-	-	-	-	-	-
B [R] Growth	-	7.61%	31.95%	-	-	-	-	-	-	-
I [T]	383M	365M	507M	-	-	-	-	-	-	-
I [T] Growth	-	-4.70%	38.90%	-	-	-	-	-	-	-
G [B]	430M	377M	498M	-	-	-	-	-	-	-
G [B] Growth	-	-12.33%	32.10%	-	-	-	-	-	-	-
V [N]	-	434M	-	-	-	-	-	-	-	-
V [N] Growth	-	-	-	-	-	-	-	-	-	-
C [O]	-	424M	-	-	-	-	-	-	-	-
C [O] Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Abbott Laboratories (ABT) has a price-to-earnings (P/E) ratio of 16.3x. This is roughly in line with market averages.

Growth & Financials

Abbott Laboratories (ABT) reported $43.84B in revenue for fiscal year 2024. This represents a 13% increase from $38.85B in 2011.

Abbott Laboratories (ABT) grew revenue by 4.6% over the past year. Growth has been modest.

Yes, Abbott Laboratories (ABT) is profitable, generating $13.98B in net income for fiscal year 2024 (31.9% net margin).

Dividend & Returns

Yes, Abbott Laboratories (ABT) pays a dividend with a yield of 1.77%. This makes it attractive for income-focused investors.

Abbott Laboratories (ABT) has a return on equity (ROE) of 30.9%. This is excellent, indicating efficient use of shareholder capital.

Abbott Laboratories (ABT) generated $6.92B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...